scholarly journals Driving Access to Care: Use of Mobile Units for Urine Specimen Collection During the Coronavirus Disease-19 (COVID-19) Pandemic

2020 ◽  
Vol 7 ◽  
pp. 237428952095355
Author(s):  
Jill S. Warrington ◽  
Alexa Brett ◽  
Heather Foster ◽  
Jamie Brandon ◽  
Samuel Francis-Fath ◽  
...  
Keyword(s):  
Substance Use ◽  
Access To Care ◽  
Substance Use Disorder ◽  
Drug Testing ◽  
Geographic Region ◽  
Urine Specimen ◽  
Mobile Unit ◽  
Increased Risk ◽  
Urine Drug Testing ◽  
Urine Drug

Patients with substance use disorders (SUD) are at increased risk of both coronavirus disease-19 complications as well as exacerbations of their current conditions due to social distancing and isolation. Innovations that provide increased access to support substance use disorder patients may mitigate long-term sequelae associated with continued or renewed drug use. To improve patient access during the coronavirus disease-19 pandemic, we deployed a mobile unit to enable access to urine drug testing where needed for patients suffering from substance use disorder. Over a 3-week pilot program, 54 patients received urine drug testing across 5 providers and 8 zip codes. The mobile unit was cost-effective, demonstrating a volume-dependent 19% lower cost compared to pre-coronavirus disease-19 patient service centers in a similar geographic region. The mobile unit was well-received by patients and providers with an average of 9 out of 10 satisfaction scores and allowed for access to urine drug testing for 67% patients who would not have received testing during this time frame. No statistically significant differences were found in substance use positivity rates in comparison to pre-coronavirus disease findings; however, some shifts in use included higher rates of fentanyl and opioid positivity and reductions in tetrahydrocannabinol and cocaine use in the mobile collections setting. Deployment of mobile collection services during the coronavirus disease-19 pandemic has shown to be an effective mechanism for supporting patients suffering from substance use disorder, allowing for access to care of this often stigmatized, vulnerable population.

scholarly journals Patient-Centered Telehealth Solution for Observed Urine Collections in Substance Use Disorder Care Delivery During COVID-19 and Beyond

2021 ◽  
Vol 8 ◽  
pp. 237437352110331
Author(s):  
Alexa Brett ◽  
Heather Foster ◽  
Michael Joseph ◽  
Jill S. Warrington
Keyword(s):  
Substance Use ◽  
Best Practices ◽  
Substance Use Disorder ◽  
Drug Testing ◽  
Care Delivery ◽  
Patient Centered ◽  
Barriers To Access ◽  
Patient Satisfaction Scores ◽  
Urine Drug Testing ◽  
Urine Drug

Patients with substance use disorder (SUD) rely upon urine drug testing to support treatment adherence and to mitigate relapse. Before the onset of coronavirus 2019 (COVID-19), the logistical challenges of randomized observed collections for urine drug testing for the patient were significant. During COVID-19, these barriers were often insurmountable. Since SUD patients represent a population at a higher risk for complications from COVID-19, an alternative strategy to support COVID-19 testing was urgently needed. We designed and deployed a telehealth-based solution in which patients could use mobile devices to connect with trained collection professionals to perform observed urine collections, often referred to a UA (urinalysis). The solution was designed with patient-centered best practices for telehealth, stigma prevention, trauma-informed, empathy and compassion, and to remove barriers to access to care. This approach demonstrated high patient satisfaction scores thereby proving that it is possible to provide urine collection services in the patient’s home via a telehealth technology, while still upholding SUD testing integrity best practices. This study lays the path for a more patient-centered way to support this population.

scholarly journals Impact of Urine Drug Testing Amongst Patients At Increased Risk of Drug-Drug Interactions

2018 ◽  
Vol 21 ◽  
pp. S178
Author(s):  
J Schrecker ◽  
C Hild ◽  
T Robert ◽  
AJ Layton ◽  
J Tang ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Drug Testing ◽  
Increased Risk ◽  
Urine Drug Testing ◽  
Urine Drug

scholarly journals Addiction and Pain Medicine

2005 ◽  
Vol 10 (suppl a) ◽  
pp. 38A-43A ◽  
Author(s):  
Douglas Gourlay
Keyword(s):  
Substance Abuse ◽  
Health Care Professionals ◽  
Drug Testing ◽  
Abuse Liability ◽  
Cannabis Use ◽  
Increased Risk ◽  
Urine Drug Testing ◽  
Urine Drug ◽  
History Of ◽  
Administration Methods

The adequate cotreatment of chronic pain and addiction disorders is a complex and challenging problem for health care professionals. There is great potential for cannabinoids in the treatment of pain; however, the increasing prevalence of recreational cannabis use has led to a considerable increase in the number of people seeking treatment for cannabis use disorders. Evidence that cannabis abuse liability is higher than previously thought suggests that individuals with a history of substance abuse may be at an increased risk after taking cannabinoids, even for medicinal purposes. Smoked cannabis is significantly more reinforcing than other cannabinoid administration methods. In addition, it is clear that the smoked route of cannabis delivery is associated with a number of adverse health consequences. Thus, there is a need for pharmaceutical-grade products of known purity and concentration using delivery systems optimized for safety. Another factor that needs to be considered when assessing the practicality of prescribing medicinal cannabinoids is the difficulty in differentiating illicit from prescribed cannabinoids in urine drug testing. Overall, a thorough assessment of the risk/benefit profile of cannabinoids as they relate to a patient’s substance abuse history is suggested.

Analytical and technical aspects of testing for drug abuse: confirmatory procedures.

1988 ◽  
Vol 34 (3) ◽  
pp. 471-473 ◽  
Author(s):  
M A Peat
Keyword(s):  
Drug Testing ◽  
Analytical Procedure ◽  
Gas Chromatography Mass Spectrometry ◽  
Technical Aspects ◽  
Governmental Agencies ◽  
Accuracy And Precision ◽  
Urine Drug Testing ◽  
Urine Drug ◽  
Chemical Technique ◽  
Layer Chromatography

Abstract Many laboratories are now performing urine drug testing for employers, governmental agencies, and other institutions. It is now recognized that presumptive positive screening results have to be confirmed by an analytical procedure based on a different chemical technique with greater than or equal sensitivity to the screening test. Thin-layer chromatography has been widely used for this; however, it is relatively insensitive for certain drugs, and it cannot satisfy the accuracy and precision requirements needed to determine threshold concentrations reliably. Gas chromatography-mass spectrometry is able to satisfy these threshold requirements and has become the method of choice for confirming initial immunoassay results.

Use of LC-HRMS in full scan-XIC mode for multi-analyte urine drug testing - a step towards a ‘black-box’ solution?

2017 ◽  
Vol 52 (8) ◽  
pp. 497-506 ◽  
Author(s):  
N. N. Stephanson ◽  
P. Signell ◽  
A. Helander ◽  
O. Beck
Keyword(s):  
Drug Testing ◽  
Black Box ◽  
Urine Drug Testing ◽  
Urine Drug ◽  
Full Scan

Estimating the Prevalence of Opiates Use by Unlinked Anonymous Urine Drug Testing: A Pilot Study in Iran

2008 ◽  
Vol 43 (3-4) ◽  
pp. 513-520 ◽  
Author(s):  
Nouzar Nakhaee ◽  
Kouros Divsalar ◽  
Manzume Shamsi Meimandi ◽  
Shahriar Dabiri
Keyword(s):  
Pilot Study ◽  
Drug Testing ◽  
Urine Drug Testing ◽  
Urine Drug
Sign in / Sign up

Export Citation Format

Share Document